{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:39:14Z","timestamp":1790930354747,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Guidelines currently favor vitamin K antagonists or low-molecular-weight heparins for treatment of noncirrhotic portal vein thrombosis (ncPVT). Use of direct oral anticoagulants (DOACs) in PVT has been met with concern because of the lack of data. We conducted a retrospective study to investigate the efficacy and safety of DOACs for the treatment of ncPVT, and to compare them with standard therapies: 330 patients with ncPVT, followed-up for a mean 41.6 months, received warfarin (n = 108), enoxaparin (n = 70), rivaroxaban (n = 65), apixaban (n = 20), dabigatran (n = 8), fondaparinux (n = 2), or no anticoagulation (n = 57). The primary outcome was complete radiographic resolution (CRR) of PVT. Secondary outcomes included recanalization of occlusive PVT, cavernous transformation of the PV, development of chronic portal hypertensive symptoms (cPHS), and major bleeding. DOACs were associated with the highest CRR rates (dabigatran, 6\/8 [75%]; apixaban, 13\/20 [65%]; rivaroxaban, 42\/65 [65%]). Enoxaparin was associated with a CRR rate similar to that of the DOACs (40\/70 = 57%). Warfarin was associated with worse outcomes in this regard (CRR rate, 31% [33\/108]; hazard ratio [HR] DOACs:warfarin, 2.91; 95% confidence interval [CI], 1.87-4.52; P &amp;lt; .0001). DOACs were associated with recanalization rates similar to enoxaparin and greater than warfarin (HR DOACs:warfarin, 3.45; 95% CI, 1.93-6.18; P &amp;lt; .0001). DOACs were associated with lower rates of cPHS, although this did not attain significance (DOACs, 8\/93 [9%]; enoxaparin, 13\/70 [19%]; warfarin, 31\/108 [29%]). DOACs were associated with less major bleeding relative to warfarin (HR DOACs:warfarin, 0.20; 95% CI, 0.05-0.86; P = .0307). Patients harboring JAK2V617F, those with no evident predisposing factor for PVT, and those with occlusive thrombus demonstrated worse outcomes. DOACs appear effective and safe for the treatment of ncPVT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001310","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:41:13Z","timestamp":1582198873000},"page":"655-666","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":85,"title":["The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-1307","authenticated-orcid":false,"given":"Leonard","family":"Naymagon","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zubizarreta","sequence":"first","affiliation":[{"name":"Department of Population Health Science and Policy\/Tisch Cancer Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"first","affiliation":[{"name":"Department of Population Health Science and Policy\/Tisch Cancer Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Troy","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schiano","sequence":"first","affiliation":[{"name":"Division of Liver Diseases, Recanati\/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"issue":"6","key":"2020022511294752600_B1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"2020022511294752600_B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjmed.2009.05.023","article-title":"Portal vein thrombosis","volume":"123","author":"Parikh","year":"2010","journal-title":"Am J Med"},{"issue":"2","key":"2020022511294752600_B3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3748\/wjg.v16.i2.143","article-title":"Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment","volume":"16","author":"Ponziani","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2020022511294752600_B4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12916-018-1069-8","article-title":"Transient portal vein thrombosis in liver cirrhosis","volume":"16","author":"Qi","year":"2018","journal-title":"BMC Med"},{"issue":"2","key":"2020022511294752600_B5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"key":"2020022511294752600_B6","article-title":"Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician [published online ahead of print 6 September 2018]","author":"Basili","journal-title":"Therap Adv Gastroenterol"},{"issue":"2 Suppl","key":"2020022511294752600_B7","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"1","key":"2020022511294752600_B8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-015-1308-1","article-title":"Guidance for the management of venous thrombosis in unusual sites","volume":"41","author":"Ageno","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"25","key":"2020022511294752600_B9","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I treat splanchnic vein thrombosis","volume":"124","author":"Ageno","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2020022511294752600_B10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"2020022511294752600_B11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2020022511294752600_B12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"2020022511294752600_B13","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"2020022511294752600_B14","doi-asserted-by":"crossref","first-page":"8432781","DOI":"10.1155\/2018\/8432781","article-title":"Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis","volume":"2018","author":"Priyanka","year":"2018","journal-title":"Int J Hepatol"},{"issue":"1","key":"2020022511294752600_B15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2020022511294752600_B16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment","volume":"41","author":"Burnett","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2020022511294752600_B17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"8","key":"2020022511294752600_B18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2016.10402","article-title":"Time in therapeutic range in warfarin-treated patients: is very good good enough?","volume":"316","author":"Passman","year":"2016","journal-title":"JAMA"},{"issue":"16","key":"2020022511294752600_B19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1161\/CIRCULATIONAHA.116.026854","article-title":"Time in the therapeutic range for patients taking warfarin in clinical trials: useful, but also misleading, misused, and overinterpreted","volume":"135","author":"Reiffel","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"2020022511294752600_B20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11239-019-01932-8","article-title":"Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin","volume":"49","author":"Houghton","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"2020022511294752600_B21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2020022511294752600_B22","first-page":"CD010956","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis","author":"Robertson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2020022511294752600_B23","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1160\/TH17-03-0210","article-title":"Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism","volume":"117","author":"Coleman","year":"2017","journal-title":"Thromb Haemost"},{"issue":"11","key":"2020022511294752600_B24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"2020022511294752600_B25","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1055\/s-0038-1673689","article-title":"Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice","volume":"118","author":"Weycker","year":"2018","journal-title":"Thromb Haemost"},{"issue":"12","key":"2020022511294752600_B26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2020022511294752600_B27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11239-017-1479-z","article-title":"Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER\u00ae, RE-COVERTM II, and RE-MEDYTM","volume":"43","author":"Feuring","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"2020022511294752600_B28","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cgh.2008.07.031","article-title":"Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation","volume":"6","author":"Turnes","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2020022511294752600_B29","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.3390\/medicina55010015","article-title":"The quality of anticoagulation therapy among warfarin-treated patients with atrial fibrillation in a primary health care setting","volume":"55","author":"Urbonas","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"23 Suppl 1","key":"2020022511294752600_B30","first-page":"I22","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"2020022511294752600_B31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier","year":"2010","journal-title":"Hepatology"},{"issue":"11","key":"2020022511294752600_B32","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1572-0241.2007.01477.x","article-title":"Prognostic factors in noncirrhotic patients with splanchnic vein thromboses","volume":"102","author":"Amitrano","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2020022511294752600_B33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.thromres.2018.12.019","article-title":"Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: a retrospective cohort study","volume":"174","author":"Acuna-Villaorduna","year":"2019","journal-title":"Thromb Res"},{"key":"2020022511294752600_B34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"issue":"3","key":"2020022511294752600_B35","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"9","key":"2020022511294752600_B36","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2020022511294752600_B37","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol"},{"issue":"7","key":"2020022511294752600_B38","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","article-title":"Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data","volume":"6","author":"Kushnir","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/4\/655\/1717347\/advancesadv2019001310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/4\/655\/1717347\/advancesadv2019001310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:30:17Z","timestamp":1582630217000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/4\/655\/452520\/The-efficacy-and-safety-of-direct-oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001310","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}